Niklas Klümper
@niklaskluemper.bsky.social
GU oncologist, Interested in precision oncology. ADC biomarker development. NECTIN4. Clinician Scientist. PI of translational research group at the University Hospital Bonn. Opinions are my own
Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12…
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social
December 11, 2024 at 9:12 AM
Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12…
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social
➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases!
@ptarantinomd.bsky.social @markuseckstein3.bsky.social